Discover
APGE
Apogee Therapeutics, Inc.
135.07
2 x 96.59
2 x 171.87
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
135.11 +0.04 (0.03%)
| Ytd | 78.95% | |
| 1y | 256.76% |
135.06
day range
135.09
35.39
52 week range
135.09
| Open | 135.06 | Prev Close | 135.07 | Low | 135.06 | High | 135.09 | Mkt Cap | 10.22B |
| Vol | 0.00 | Avg Vol | 2.93M | EPS | -4.34 | P/E | N/A | Forward P/E | -26.00 |
| Beta | 0.33 | Short Ratio | 3.63 | Inst. Own | 110.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 134.18 | 200-d Avg | 93.12 | 1yr Est | 134.62 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-09 | 2026-09 | -1.14 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -1.07 | -1.14 | -0.07 | -6.54% |
| 2026-05-11 | 2026-03 | -1.07 | -1.06 | 0.01 | 0.93% |
| 2026-03-02 | 2025-12 | -1.05 | -1.03 | 0.02 | 1.90% |
| 2025-11-10 | 2025-09 | -1.12 | -1.11 | 0.01 | 0.89% |
| 2025-08-11 | 2025-06 | -1.03 | -1.13 | -0.1 | -9.71% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-13 | Truist Securities | Upgrade | Hold | Hold |
| 2026-08-12 | BTIG | Downgrade | Buy | Neutral |
| 2026-06-24 | Stifel | Downgrade | Buy | Hold |
| 2026-06-24 | TD Cowen | Downgrade | Buy | Hold |
| 2026-06-24 | Guggenheim | Downgrade | Buy | Neutral |
| 2026-06-24 | Mizuho | Downgrade | Outperform | Neutral |
Profile
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-04 | DAMBKOWSKI CARL | Officer | 168.50K | Sale |
| 2026-08-06 | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-07-23 | HENDERSON JANE | Chief Financial Officer | 158.37K | Stock Gift |
| 2026-07-09 | HENDERSON MICHAEL THOMAS | Chief Executive Officer | 920.94K | Stock Gift |
| 2024-12-11 | MCKENNA MARK C | Director | 20.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Venrock Adviser, LLC | 8.49M | 1.15B | 13.65% |
| 2026-06-29 | Blackrock Inc. | 5.51M | 743.83M | 8.85% |
| 2026-06-29 | HBK Investments L P | 2.85M | 384.95M | 4.58% |
| 2026-06-29 | Vanguard Capital Management LLC | 2.57M | 347.42M | 4.14% |
| 2026-06-29 | FMR, LLC | 2.49M | 336.75M | 4.01% |
| 2026-06-29 | State Street Corporation | 2.30M | 310.36M | 3.69% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.87M | 252.67M | 3.01% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.49M | 201.35M | 2.40% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.20M | 162.58M | 1.94% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.16M | 156.35M | 1.86% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 673.95K | 91.03M | 1.08% |
| 2026-06-29 | T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq | 653.46K | 88.26M | 1.05% |